Cargando…
Patient attitudes and understanding about biosimilars: an international cross-sectional survey
OBJECTIVE: To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889091/ https://www.ncbi.nlm.nih.gov/pubmed/27307714 http://dx.doi.org/10.2147/PPA.S104891 |
_version_ | 1782434945163067392 |
---|---|
author | Jacobs, Ira Singh, Ena Sewell, K Lea AL-Sabbagh, Ahmad Shane, Lesley G |
author_facet | Jacobs, Ira Singh, Ena Sewell, K Lea AL-Sabbagh, Ahmad Shane, Lesley G |
author_sort | Jacobs, Ira |
collection | PubMed |
description | OBJECTIVE: To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy groups impact patients’ willingness to try a biosimilar. METHODS: An international survey was conducted which contained up to 56 closed-ended (requiring yes/no or ranking answers) and open-ended questions, depending on the population assigned. The survey was divided into distinct sections, including medication-class awareness, usage, and knowledge about biologic and biosimilar therapies; perceptions of clinical trials; and involvement in advocacy groups. Interviews were conducted in adults categorized as: 1) diagnosed: patients with inflammatory bowel disease including Crohn’s disease and ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, colorectal cancer, or non-Hodgkin’s lymphoma; 2) diagnosed advocacy: individuals with these diseases who participated in patient support groups; 3) caregiver: has a loved one with these conditions and is involved in medical decisions; 4) general population: aged 18–64 years, without these conditions. Statistical analyses among groups within a region (US or EU) used column proportions test with a 95% confidence interval. RESULTS: In all, 3,198 individuals responded. Awareness about biologic therapies was significantly higher in diagnosed, diagnosed advocacy, and caregiver groups (45%–78%) versus general population (27%; P<0.05). Across all groups, awareness of biosimilars was low; only 6% of the general population reported at least a general impression of biosimilars. Awareness was significantly higher in the diagnosed advocacy group (20%–30%; P<0.05). Gaps in knowledge about biosimilars included safety, efficacy, and access to these agents. Respondents had generally positive perceptions of clinical trials, although barriers to participation were identified. CONCLUSION: An immediate need exists for patient education about biosimilars and clinical trials to ensure educated and informed decisions are made about biosimilar use. |
format | Online Article Text |
id | pubmed-4889091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48890912016-06-15 Patient attitudes and understanding about biosimilars: an international cross-sectional survey Jacobs, Ira Singh, Ena Sewell, K Lea AL-Sabbagh, Ahmad Shane, Lesley G Patient Prefer Adherence Original Research OBJECTIVE: To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy groups impact patients’ willingness to try a biosimilar. METHODS: An international survey was conducted which contained up to 56 closed-ended (requiring yes/no or ranking answers) and open-ended questions, depending on the population assigned. The survey was divided into distinct sections, including medication-class awareness, usage, and knowledge about biologic and biosimilar therapies; perceptions of clinical trials; and involvement in advocacy groups. Interviews were conducted in adults categorized as: 1) diagnosed: patients with inflammatory bowel disease including Crohn’s disease and ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, colorectal cancer, or non-Hodgkin’s lymphoma; 2) diagnosed advocacy: individuals with these diseases who participated in patient support groups; 3) caregiver: has a loved one with these conditions and is involved in medical decisions; 4) general population: aged 18–64 years, without these conditions. Statistical analyses among groups within a region (US or EU) used column proportions test with a 95% confidence interval. RESULTS: In all, 3,198 individuals responded. Awareness about biologic therapies was significantly higher in diagnosed, diagnosed advocacy, and caregiver groups (45%–78%) versus general population (27%; P<0.05). Across all groups, awareness of biosimilars was low; only 6% of the general population reported at least a general impression of biosimilars. Awareness was significantly higher in the diagnosed advocacy group (20%–30%; P<0.05). Gaps in knowledge about biosimilars included safety, efficacy, and access to these agents. Respondents had generally positive perceptions of clinical trials, although barriers to participation were identified. CONCLUSION: An immediate need exists for patient education about biosimilars and clinical trials to ensure educated and informed decisions are made about biosimilar use. Dove Medical Press 2016-05-26 /pmc/articles/PMC4889091/ /pubmed/27307714 http://dx.doi.org/10.2147/PPA.S104891 Text en © 2016 Jacobs et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Jacobs, Ira Singh, Ena Sewell, K Lea AL-Sabbagh, Ahmad Shane, Lesley G Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title | Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title_full | Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title_fullStr | Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title_full_unstemmed | Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title_short | Patient attitudes and understanding about biosimilars: an international cross-sectional survey |
title_sort | patient attitudes and understanding about biosimilars: an international cross-sectional survey |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889091/ https://www.ncbi.nlm.nih.gov/pubmed/27307714 http://dx.doi.org/10.2147/PPA.S104891 |
work_keys_str_mv | AT jacobsira patientattitudesandunderstandingaboutbiosimilarsaninternationalcrosssectionalsurvey AT singhena patientattitudesandunderstandingaboutbiosimilarsaninternationalcrosssectionalsurvey AT sewellklea patientattitudesandunderstandingaboutbiosimilarsaninternationalcrosssectionalsurvey AT alsabbaghahmad patientattitudesandunderstandingaboutbiosimilarsaninternationalcrosssectionalsurvey AT shanelesleyg patientattitudesandunderstandingaboutbiosimilarsaninternationalcrosssectionalsurvey |